Corbus Pharmaceuticals Holdings, Inc. short interest in 2026
In 2026, Corbus Pharmaceuticals Holdings, Inc.'s disclosed short interest ran from 7.49% of shares outstanding on 15 Jan 2026 to 14.27% on 15 Sep 2026, a change of +6.78 percentage points. The year's high was 14.27% on 15 Sep 2026 and its low 6.45% on 15 May 2026, averaging 9.08% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.38 days on 31 Jul 2026. Full history: Corbus Pharmaceuticals Holdings, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 7.49% (15 Jan 2026)
- End of year
- 14.27% (15 Sep 2026)
- Change
- +6.78 pp
- High
- 14.27% (15 Sep 2026)
- Low
- 6.45% (15 May 2026)
- Average
- 9.08%
- Highest days to cover
- 9.38 (31 Jul 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 7.49% | 7.09 | |
| 30 Jan 2026 | 7.63% | 8.38 | |
| 13 Feb 2026 | 7.46% | 9.03 | |
| 27 Feb 2026 | 7.50% | 8.01 | |
| 13 Mar 2026 | 7.48% | 5.19 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 6.83% | 6.30 | |
| 15 Apr 2026 | 7.58% | 6.13 | |
| 30 Apr 2026 | 7.94% | 4.61 | |
| 15 May 2026 | 6.45% | 3.90 | 10-Q filed, results (8-K) |
| 29 May 2026 | 8.25% | 1.43 | |
| 15 Jun 2026 | 8.53% | 3.39 | |
| 30 Jun 2026 | 10.50% | 3.40 | |
| 15 Jul 2026 | 11.31% | 5.90 | |
| 31 Jul 2026 | 12.41% | 9.38 | |
| 14 Aug 2026 | 11.10% | 6.04 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 11.61% | 3.67 | |
| 15 Sep 2026 | 14.27% | 1.54 |
See also: Corbus Pharmaceuticals Holdings, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.